Cellmid Limited

Suite 1802, Level 18 15 Castlereagh Street
Sydney, NSW 2000 Australia
Phone
Fax
Click for website

Research Sector Diagnostics & Therapeutics

Summary Description Cellmid Limited (ASX:CDY) is a biotechnology company listed on the Australian Stock Exchange. The company is developing innovative therapies and diagnostic tests for heart attack, inflammatory diseases and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine, an extensively validated therapeutic and diagnostic target in inflammation, autoimmunity and cancer. Cellmid is actively looking for partners to commercialise these significant midkine intellectual property assets in ischemia, cancer and inflammatory diseases.

Management Dr David King, Chairman; Ms Maria Halasz, Managing Director and Chief Executive Officer; Mr Graeme Kaufman, Non-Executive Director; Mr Martin Rogers, Non-Executive Director; Mr Darren Jones, Head of Product Development; Mr Nicholas Falzon, Company Secretary & Financial Controller; Ms Jillian McGregor, Company Secretary

Click here for Financial Data
Keywords: cancer, oncology, inflammation, therapy, therapeutic

Comment


Updated: Oct. 28, 2015


Description

Cellmid Limited (ASX:CDY) is a biotechnology company listed on the Australian Stock Exchange. The company is developing innovative therapies and diagnostic tests for heart attack, inflammatory disease......view more

Products / Services

MidKine Kit......view more

Technology / Differentiation

Discovered in 1988 by Professors Takashi Muramatsu and Kenji Kadomatsu, MK is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important bi...view more

RELATED COMPANIES